Cardiology

Long-Term Care and Monitoring

At a Glance

Long-term care for sensorineural deafness with dilated cardiomyopathy combines personalized heart and hearing checks with genetic family screening and risk assessment. Regular follow-up can detect changes early, while counseling and hearing technology support quality of life.

A diagnosis of a cardio-auditory phenotype is not a single event; it is the beginning of a lifelong commitment to long-term care and monitoring. Because these conditions are progressive, care means staying ahead of changes in your heart and hearing so that your medical team can adjust your care before symptoms become disruptive ^[1]^[2].

Recommended Monitoring Intervals

While there is no “one-size-fits-all” schedule for every genetic variant, medical consensus favors a risk-based approach tailored to your specific gene and current health status ^[3].

For Affected Individuals:
- Cardiac Surveillance: Most stable patients receive an electrocardiogram (ECG) and echocardiogram at intervals based on their age and specific gene ^[1]^[4]. If your heart function is changing or you have a higher-risk genetic variant, your doctor may shorten this to every 3–6 months ^[1].
- Auditory Surveillance: Regular audiograms (hearing tests) are the standard for Alström syndrome and are generally recommended for EYA4 and mitochondrial forms to track the rate of hearing decline ^[5]^[6].
For First-Degree Relatives:
- All parents, siblings, and children of an affected person should have at least one baseline ECG and echocardiogram ^[3]^[7].
- If a specific pathogenic or likely pathogenic genetic mutation has been identified in the family, relatives should undergo cascade screening (targeted genetic testing) ^[8]. A genetic counselor will explain which relatives actually need testing and surveillance. Those who carry the gene but have no symptoms may still need heart and hearing checks depending on their age and risk profile ^[9]^[10]. However, relatives who test true negative for a known pathogenic familial variant generally do not need lifelong surveillance. Conversely, if a genetic test only shows a “variant of uncertain significance” (VUS), predictive cascade testing is not appropriate.

Advanced Risk Stratification: Beyond Ejection Fraction

For many years, doctors used the ejection fraction (LVEF) as the primary way to decide who needed an ICD (defibrillator). However, current research shows that LVEF alone is not enough to predict the risk of sudden cardiac death (SCD) in genetic conditions ^[11]^[12]. Your team will look at several “risk markers” to inform an electrophysiology assessment:

Cardiac MRI and LGE: A cardiac MRI can detect Late Gadolinium Enhancement (LGE), which identifies areas of microscopic scarring (fibrosis) in the heart muscle ^[13]. Patients with significant scarring are at a higher risk for dangerous heart rhythms, even if their ejection fraction is relatively normal ^[11]^[14].
Clinical and Electrical Markers: A history of unexplained fainting (syncope), frequent “skipped” heartbeats (PVCs), or short bursts of a rapid heart rate (NSVT) on a heart monitor are significant red flags that influence your risk ^[15]^[16]^[17].
Genetic Risk: Certain genes are naturally more “arrhythmogenic” (prone to rhythm issues) than others. Knowing your specific mutation helps your doctor decide if you need a protective device earlier than someone else ^[12]^[18].

It is important to know that these markers are pieces of an assessment, not stand-alone indications. Having an abnormal marker does not guarantee sudden death.

Navigating the Psychosocial Impact

Living with a progressive condition that affects both your “pump” and your “senses” can lead to unique emotional challenges. It is common to experience scan anxiety—a feeling of dread or high stress in the days or weeks leading up to your annual check-ups.

Managing Progressive Change: Watching your hearing or heart function decline can feel like a loss of identity. Connecting with specialized support groups for rare diseases or hearing loss can reduce the sense of social isolation ^[19]. It is also important to remember that while some experience progression, others remain stable or improve with treatment.
Communication Benefits: If hearing loss becomes severe, technologies like cochlear implants can do more than just improve “hearing scores”—they often lead to significant gains in social-emotional well-being and quality of life by reconnecting you to your family and community ^[20]^[19].
Multidisciplinary Support: Because your health is complex, your mental health should be part of the conversation. Ask your care team for a referral to a social worker or psychologist who understands the burden of managing chronic, rare conditions ^[21]^[2].

By staying consistent with your monitoring and being honest with your team about both your physical and emotional symptoms, you can move from a state of “waiting for symptoms” to one of active, empowered long-term care ^[22]^[23].

Common questions in this guide

How often should I have heart and hearing tests?

There is no single schedule for everyone. The timing of ECGs, echocardiograms, and hearing tests depends on your age, genetic variant, heart function, and symptoms; people with changing heart function or higher-risk variants may need heart checks every 3–6 months.

Do my parents, siblings, or children need screening?

First-degree relatives—parents, siblings, and children—should have at least one ECG and echocardiogram. If the family has a known disease-causing variant, a genetic counselor can determine who needs targeted testing and ongoing heart or hearing monitoring.

Can my heart still be at risk if my ejection fraction is normal?

Yes. A normal or near-normal ejection fraction does not by itself rule out dangerous rhythm risk in genetic heart conditions. Doctors may also consider heart muscle scarring on MRI, fainting, extra or rapid heartbeats, and the specific genetic variant.

What does late gadolinium enhancement on a heart MRI mean?

Late gadolinium enhancement, or LGE, shows areas of scar tissue in the heart muscle. More extensive scarring can be linked with a higher risk of dangerous rhythms, but it is only one part of the overall assessment and does not guarantee sudden death.

What happens if a relative tests negative for our family variant?

When a relative tests negative for a known pathogenic family variant, they generally do not need lifelong heart and hearing surveillance for that inherited risk. This conclusion applies when the family variant is clearly identified; a variant of uncertain significance should not be used for predictive family testing.

How can I cope with stress about ongoing tests and disease progression?

Stress before scans and check-ups is common, and support groups for rare disease or hearing loss may reduce isolation. Ask your care team about a social worker or psychologist, and discuss hearing technologies such as cochlear implants if hearing loss is severe.

How do doctors decide whether I need an implantable defibrillator?

They do not rely on ejection fraction alone. The assessment may include heart MRI scarring, unexplained fainting, frequent extra beats, short runs of rapid rhythm, and the risk associated with your genetic variant; an abnormal marker does not guarantee sudden death.

Get notified when new evidence is published on Sensorineural deafness with dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

Monitoring schedules for ECGs, echocardiograms, and audiograms should be individualized by age, genetic variant, heart function, and current symptoms.
First-degree relatives should have baseline ECG and echocardiogram, while targeted cascade testing is guided by a known familial pathogenic or likely pathogenic variant and a genetic counselor.
Cardiac MRI scarring, fainting, PVCs, NSVT, and an arrhythmogenic gene can influence sudden rhythm risk even when ejection fraction is relatively normal.
A true negative result for a known familial pathogenic variant generally means lifelong surveillance is not needed, whereas a variant of uncertain significance should not be used for predictive cascade testing.
Support groups, mental health care, and cochlear implants when appropriate can improve coping, communication, and quality of life.

References (23)

1
The contribution of cardiopulmonary exercise testing in the familial screening for dilated and non-dilated left ventricular cardiomyopathies: case series.
Del Mestre E, Capovilla TM, Paldino A, et al.
European heart journal. Case reports 2025; (9(4)):ytaf162 doi:10.1093/ehjcr/ytaf162.
PMID: 40302978
2
Alström syndrome: a cross-sectional and follow-up study of 127 patients in China, highlighting genetic variant spectrum and cardiac features.
Huang Y, Wang L, Zhang Q, et al.
Orphanet journal of rare diseases 2025; (20(1)):630 doi:10.1186/s13023-025-04139-8.
PMID: 41466426
3
Clinical care of family members of patients with dilated cardiomyopathy.
Verdonschot JAJ, Kaski JP, Asselbergs FW, et al.
European heart journal 2025; (46(43)):4569-4582 doi:10.1093/eurheartj/ehaf571.
PMID: 40902100
4
Familial dilated cardiomyopathy: A multidisciplinary entity, from basic screening to novel circulating biomarkers.
de Gonzalo-Calvo D, Quezada M, Campuzano O, et al.
International journal of cardiology 2017; (228()):870-880 doi:10.1016/j.ijcard.2016.11.045.
PMID: 27889554
5
Hearing Loss in Adults With Alström Syndrome-Experience From the UK National Alström Service.
Quoraishi S, Mason G, Geberhiwot T, Dalton CL
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2022; (43(6)):e620-e627 doi:10.1097/MAO.0000000000003553.
PMID: 35761454
6
Auditory and otologic profile of Alström syndrome: Comprehensive single center data on 38 patients.
Lindsey S, Brewer C, Stakhovskaya O, et al.
American journal of medical genetics. Part A 2017; (173(8)):2210-2218 doi:10.1002/ajmg.a.38316.
PMID: 28573831
7
Screening for Dilated Cardiomyopathy in At-Risk First-Degree Relatives.
Ni H, Jordan E, Kinnamon DD, et al.
Journal of the American College of Cardiology 2023; (81(21)):2059-2071 doi:10.1016/j.jacc.2023.03.419.
PMID: 37225358
8
Yield of family screening for dilated cardiomyopathy: 10-year experience at a multidisciplinary cardiogenetic outpatient clinic.
Thierry IP, Muller SA, Baas AF, et al.
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation 2025; (33(2)):46-54 doi:10.1007/s12471-024-01924-1.
PMID: 39833651
9
Optimizing Screening Intervals for At-Risk Relatives of Dilated Cardiomyopathy Carrying a TTNtv.
Muller SA, Beelen NJ, Paldino A, et al.
Circulation. Heart failure 2026; e013822 doi:10.1161/CIRCHEARTFAILURE.125.013822.
PMID: 42765307
10
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives.
Cabrera-Romero E, Ochoa JP, Barriales-Villa R, et al.
Journal of the American College of Cardiology 2024; (83(17)):1640-1651 doi:10.1016/j.jacc.2024.02.036.
PMID: 38658103
11
Improved Risk Stratification for Ventricular Arrhythmias and Sudden Death in Patients With Nonischemic Dilated Cardiomyopathy.
Di Marco A, Brown PF, Bradley J, et al.
Journal of the American College of Cardiology 2021; (77(23)):2890-2905 doi:10.1016/j.jacc.2021.04.030.
PMID: 34112317
12
Genotype and arrhythmic risk in dilated cardiomyopathy.
Padalia K, Fornaro A, Claggett B, et al.
European heart journal 2026; doi:10.1093/eurheartj/ehag648.
PMID: 42864989
13
Diffuse left ventricular interstitial fibrosis is associated with sub-clinical myocardial dysfunction in Alström Syndrome: an observational study.
Edwards NC, Moody WE, Yuan M, et al.
Orphanet journal of rare diseases 2015; (10()):83 doi:10.1186/s13023-015-0292-z.
PMID: 26104972
14
Impact of late gadolinium-enhanced cardiac MRI on arrhythmic and mortality outcomes in nonischemic dilated cardiomyopathy: updated systematic review and meta-analysis.
Theerasuwipakorn N, Chokesuwattanaskul R, Phannajit J, et al.
Scientific reports 2023; (13(1)):13775 doi:10.1038/s41598-023-41087-4.
PMID: 37612359
15
Role of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy.
Setti M, Merlo M, Gigli M, et al.
European journal of heart failure 2024; (26(3)):581-589 doi:10.1002/ejhf.3168.
PMID: 38404225
16
Predictive value of ambulatory ECG monitoring for malignant arrhythmic events in genetic dilated cardiomyopathy.
Venner MFGHM, Heymans ABM, Beelen NJ, et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2025; (27(11)) doi:10.1093/europace/euaf279.
PMID: 41206691
17
Nonsustained Ventricular Tachycardia Is Independently Associated With Sustained Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy.
Piers SR, Androulakis AF, Yim KS, et al.
Circulation. Arrhythmia and electrophysiology 2022; (15(2)):e009979 doi:10.1161/CIRCEP.121.009979.
PMID: 35089806
18
Genetic Risk of Arrhythmic Phenotypes in Patients With Dilated Cardiomyopathy.
Gigli M, Merlo M, Graw SL, et al.
Journal of the American College of Cardiology 2019; (74(11)):1480-1490 doi:10.1016/j.jacc.2019.06.072.
PMID: 31514951
19
Bilateral Cochlear Implantation: A Health Technology Assessment.

Ontario health technology assessment series 2018; (18(6)):1-139.
PMID: 30443278
20
Cochlear implantation and mastoid obliteration in a patient with Alström Syndrome.
Hill RG, Dwyer K, Tirino J, Whitley M
International journal of pediatric otorhinolaryngology 2020; (132()):109894 doi:10.1016/j.ijporl.2020.109894.
PMID: 32014736
21
[Current indications for cochlear implantation].
Jakob TF, Aschendorff A, Ketterer MC, et al.
HNO 2026; (74(4)):251-262 doi:10.1007/s00106-026-01744-2.
PMID: 41718821
22
Evaluation of the NHS R67 Monogenic Hearing Loss Panel in a Single UK Centre.
Sakin I, Swords C, Ball J, et al.
Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2026; (51(5)):708-713 doi:10.1111/coa.70125.
PMID: 42200350
23
Genetics evaluation outcomes of patients with pediatric hearing loss: 2008-2022 retrospective study.
Mazzola S, Schreiber A
American journal of otolaryngology 2024; (45(2)):104196 doi:10.1016/j.amjoto.2023.104196.
PMID: 38134852

This page provides general information about long-term heart, hearing, genetic, and emotional monitoring for sensorineural deafness with dilated cardiomyopathy; it is not medical advice. Your cardiology, audiology, and genetics teams should tailor testing and treatment to your genetic findings, age, symptoms, and family history.